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Background: Granulocyte colony-stimulating factor (G-CSF) can induce regulatory T cells (Tregs) as well as myeloid-
derived suppressor cells (MDSCs). Despite the immune modulatory effects of G-CSF, results of G-CSF treatment in
systemic lupus erythematosus are still controversial. We therefore investigated whether G-CSF can ameliorate lupus
nephritis and studied the underlying mechanisms.
Methods: NZB/W F1 female mice were treated with G-CSF or phosphate-buffered saline for 5 consecutive days
every week from 24 weeks of age, and were analyzed at 36 weeks of age.
Results: G-CSF treatment decreased proteinuria and serum anti-dsDNA, increased serum complement component
3 (C3), and attenuated renal tissue injury including deposition of IgG and C3. G-CSF treatment also decreased
serum levels of BUN and creatinine, and ultimately decreased mortality of NZB/W F1 mice. G-CSF treatment
induced expansion of CD4+CD25+Foxp3+ Tregs, with decreased renal infiltration of T cells, B cells, inflammatory
granulocytes and monocytes in both kidneys and spleen. G-CSF treatment also decreased expression levels of
MCP-1, IL-6, IL-2, and IL-10 in renal tissues as well as serum levels of MCP-1, IL-6, TNF-α, IL-10, and IL-17. When
Tregs were depleted by PC61 treatment, G-CSF-mediated protective effects on lupus nephritis were abrogated.
Conclusions: G-CSF treatment ameliorated lupus nephritis through the preferential expansion of CD4+CD25+Foxp3
+ Tregs. Therefore, G-CSF has a therapeutic potential for lupus nephritis.
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Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease in which altered T cell function and polyclonal B cell
activation followed by autoantibody production including
anti-double stranded DNA antibodies (anti-dsDNA), thus,
leading to immune complex deposition in multiple organs,
particularly in the kidney. These depositions drive local in-
flammatory responses that can lead to tissue damage and
clinical disease [1, 2].* Correspondence: jcyjs@dreamwiz.com
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(http://creativecommons.org/publicdomain/zeGranulocyte colony-stimulating factor (G-CSF) is a
growth factor for neutrophils, that can accelerate neu-
trophil reconstitution after bone marrow suppression
and activate effector functions of mature neutrophils
[3]. G-CSF also stimulates proliferation, differentiation,
and peripheral mobilization of hematopoietic stem cells
[3]. Furthermore, G-CSF has been reported to modulate
both T cell and innate immune responses. G-CSF can
induce Tr1 cells in vitro, and mobilize CD4+CD25
+Foxp3 regulatory T cells (Tregs) [4, 5]. In addition, G-
CSF can mobilize human tolerogenic dendritic cells and
induce human semi-mature dendritic cells, and thereby
induce type 1 regulatory T (Tr1) cells through interleu-
kin (IL)-10 release [6, 7]. G-CSF suppresses production
of IL-1β, IL-12, interferon (IFN)-γ, and tumor necrosis
factor (TNF)-α, but increases serum levels of IFN-αle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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induce CD11b+Gr-1+ myeloid-derived suppressor cells
(MDSC), a subset of innate-like suppressor cells [9, 10].
MDSCs are a heterogeneous population of immature
myeloid cells that can suppress both T cells and natural
killer (NK) cells and thereby suppress autoimmunity as
well as tumor immunity [10, 11]. MDSCs are divided
into two subsets, granulocytic MDSCs (CD11b+Ly6G
+Ly6Clow), and monocytic MDCSs (CD11b+Ly6G-
Ly6Chigh) [10]. However, CD11b+Ly6G+Ly6Clow and
CD11b+Ly6G-Ly6Chigh cells could be inflammatory
granulocytes and inflammatory monocytes, respectively,
because these populations share surface markers with
MDSCs.
Despite the immunomodulatory effects of G-CSF, re-
sults of G-CSF treatment in SLE are still controversial.
Low-dose G-CSF treatment accelerated lupus nephritis
in MRL lymphoproliferation (MRL/lpr) strain mice and
increased autoantibody production in B6.Sle1.Sle2.Sle3
spontaneous mouse model of lupus [12, 13]. In contrast,
high-dose G-CSF treatment prevented lupus nephritis
and delayed mortality [13]. In patients, G-CSF induced
disease flares in both lupus nephritis and cutaneous lupus
[14, 15]. These controversial results require further study
to confirm the role of G-CSF in lupus nephritis and to de-
termine the involved mechanisms. In this study, we inves-
tigated whether G-CSF can ameliorate lupus nephritis in a
NZB/W F1 mouse lupus model, and examined the related
mechanisms.
Methods
Animals and treatment regimens
NZB/W F1 mice spontaneously develop a disease
closely resembling human SLE [16]. Female NZB/W F1
mice were purchased from SLC Inc. (Hamamatsu,
Japan) and housed under the pathogen-free conditions.
The experimental group was injected subcutaneously
with recombinant human G-CSF (Grasin, Kyowa Kirin,
Korea) for 5 consecutive days every week from 24 weeks
of age, at a dose of 250 μg/kg/day during 12 weeks. In
low-dose experiments, 250 μg/kg/day of human G-CSF
was administered 3 times a week for 12 weeks from
24 weeks of age. The control group received only
phosphate-buffered saline (PBS) injection. For Treg de-
pletion, depleting anti-CD25 antibodies (PC61, Bio X
Cell, West Lebanon, NH, USA) were administered at a
dose of 0.5 mg 3 times a week from 33 to 36 weeks.
Measurement of proteinuria, renal function, anti-dsDNA,
complement component 3 (C3), and cytokines
Spot urine proteinuria was measured using protein reagent
strips (URiSCAN; Yongdong Pharmaceutical Co., Seoul,
Korea) once per week for 12 weeks. The measurement was
semi-quantitative: 0 = none or trace amount of proteinuria,1+, 30–100 mg/dL; 2+, 100–300 mg/dL; 3+, 300–
1000 mg/dL; 4+, ≥ 1000 mg/dL. Urine albumin concentra-
tions were measured using a mouse albumin ELISA kit
(Alpco Diagnostics, Salem, NH, USA) and normalized to
urine creatinine concentrations. Serum levels of BUN and
creatinine were measured at 32 and 36 weeks using Quan-
tiChrom urea and creatinine assay kits (BioAssay Systems,
Hayward, CA, USA) [17]. Serum concentration of mouse
anti-dsDNA and C3 were measured using ELISA kits
(Alpha Diagnostic International, San Antonio, TX, USA;
Abcam, Cambridge, MA, USA) at 36 weeks. Levels of
monocyte chemoattractant protein-1 (MCP-1) and cyto-
kines (IL-6, TNF-α, IL-2, IFN-γ, IL-10, IL-4 and IL-17)
were measured at 36 weeks in both serum and renal tissues
using cytometric bead array kits (BD Biosciences, San
Diego, CA, USA).
Renal histologic analysis
Paraffin sections of fixed kidneys were stained with Periodic
Acid-Schiff ’s (PAS) stain kit, and evaluated according to
described protocol [18, 19]. Briefly, glomerular path-
ology was evaluated by assessing 20 glomerular cross-
sections (gcs) per kidney, and each glomerulus was
scored on a semiquantitative scale: 0 = normal (35–40
cells/glomerular cross-sections, gcs); 1 =mild (glomeruli
with few lesions, slight proliferative changes, mild hyper-
cellularity, 41–50 cells/gcs); 2 =moderate (glomeruli with
moderate hypercellularity, 50–60 cells/gcs, segmental
and/or diffuse proliferative changes, hyalinosis); 3 = severe
(glomeruli with segmental or global sclerosis, and/or
exhibiting severe hypercellularity (>60 cells/gcs), necrosis,
crescent formation). Interstitial/tubular pathology was
assessed semiquantitatively on a scale of 0–3 in 10 ran-
domly selected high-power fields. We determined the
largest and average number of infiltrates and damaged
tubules and subsequently adjusted the grading system
accordingly: 0, normal; 1, mild; 2, moderate; 3, severe.
Perivascular cellular accumulation was determined semi-
quantitatively by scoring the number of cell layers sur-
rounding the majority of vessel walls (0, none; 1, < 5; 2, 5–
10; 3, ≥ 10 cell layers).
Kidney cryostat sections were stained with goat anti-
mouse IgG (Sigma-Aldrich) or rabbit anti-mouse C3
(Abcam) for 4 h. Then, they were incubated at room
temperature with Alexa Fluor 488 donkey anti-goat IgG
or Alexa Fluor 568 donkey anti-rabbit IgG (Molecular
Probe; Invitrogen USA) for 1 h. Deposition of IgG and C3
within the peripheral glomerular capillary walls and the
mesangium was measured as the mean fluorescence in 10
glomeruli per mouse. Scores were assigned based on the
intensity of IgG/C3 deposition (0–3+), where 0 represents
no deposition and 3 denotes intense deposition [20]. All
histologic analysis was performed by two independent pa-
thologists blinded to the treatment group.
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Renal leukocytes and splenocytes were pretreated with
anti-mouse CD16/32 (clone 2.4G2) to block nonspecific
Fc binding. Kidney leukocytes were identified by labeling
cells with CD45 (30-F11). The fluorochrome-conjugated
antibodies (BD Biosciences or eBioscience) were usedFig. 1 (See legend on next page.)for flow cytometric analysis: CD45 (30-F11), CD3 (145-
2C11), CD4 (RM4-5), CD8 (53-6.7), CD25 (ebioPC61),
CD44 (IM7), CD69 (H1.2 F3), Foxp3 (ebio), CD11b
(M1/70), Gr-1 (RB6-BC5, ebio), Ly6G (RB6-8c5), Ly6C
(AL-21), CD19 (eBio1D3), CD138 (281-2), CXCR5
(SPRCL5), PD-1 (J43), NK1.1 (PK136). Appropriate
(See figure on previous page.)
Fig. 1 G-CSF treatment ameliorated disease activity, proteinuria, and mortality in lupus nephritis. a The G-CSF group had significantly lower pro-
teinuria than the PBS group throughout the study period (P < 0.01, generalized estimating equation). When we decreased Tregs by PC61 adminis-
tration at a dose of 0.5 mg 3 times a week during G-CSF treatment, Treg reduction abrogated beneficial effects of G-CSF on proteinuria. b Urine
albumin/creatinine ratio was also significantly decreased at 32 (P < 0.01) and 36 weeks (P < 0.05) in the G-CSF group. c The G-CSF group had bet-
ter survival rates than the PBS group (P < 0.05, log-rank test). d-e Serum levels of BUN (d) at 32 weeks and creatinine (e) at 32 and 36 weeks were
significantly decreased by G-CSF treatment (P < 0.05, t test). f Serum levels of anti-dsDNA at 36 weeks were significantly lower in the G-CSF group
(P < 0.05, t-test). g Serum C3 levels at 36 weeks were significantly higher in the G-CSF group (P < 0.05, t-test). The data are expressed as the mean
± standard error of the mean, with n = 14 − 16 mice per group. White and black bars indicate the G-CSF group and the PBS group, respectively.
*P < 0.05, **P < 0.01 for comparisons between the G-CSF and the PBS groups. C3: complement component 3; G-CSF: granulocyte colony-
stimulating factor; PBS: phosphate-buffered saline
Yan et al. BMC Nephrology  (2016) 17:175 Page 4 of 12fluorochrome-conjugated isotype-matched irrelevant
monoclonal antibodies were used as negative controls.
7-aminoactinomycin D was also added to distinguish be-
tween live and dead cells. The stained cells were ana-
lyzed using BD FACSCanto II (BD Biosciences).
Statistical analysis
Data were expressed as the mean ± standard error of the
mean (SEM). Student’s t-test was used to compare means.
Survival rates were analyzed using the Kaplan-Meier
method and compared by the log-rank test. Difference in
proteinuria during treatment was analyzed using general-
ized estimating equations. P values of less than 0.05 were
considered statistically significant. All data were analyzed
using SPSS v.22.0 software (SPSS Inc., Chicago, IL, USA).
Results
G-CSF treatment ameliorated lupus-like disease in NZB/
W F1 mice
Proteinuria from semi-quantitative measurement values
was around 1.5 in most mice at 24 weeks of age. After
24 weeks, proteinuria gradually increased, reaching up to
3.3 in the PBS group. In contrast, proteinuria was main-
tained at a low level in the G-CSF group (P < 0.01, Fig. 1a).
Urine albumin/creatinine ratio was significantly decreased
at 32 weeks (P < 0.01) and 36 weeks (P < 0.05) in the G-
CSF group (Fig. 1b). At 36 weeks of age, 27 % of mice in
the PBS group had died, whereas there was no mortality
in the G-CSF group (P < 0.05, Fig. 1c). Serum levels of
BUN (Fig. 1d) and creatinine (Fig. 1e) were significantly
lower in the G-CSF group compared with the PBS group
(P < 0.05). G-CSF treatment decreased serum levels of
anti-dsDNA IgG (P < 0.05, Fig. 1f) and increased serum
levels of C3 (P < 0.05, Fig. 1g).
G-CSF treatment attenuated renal pathologic injury
Renal injury in NZB/W F1 mice consisted of glomerular,
interstitial, and perivascular infiltration of monocytes and
lymphocytes, and concomitant immune complex depos-
ition [21, 22]. NZB/W F1 mice in the PBS group exhibited
severe renal injury, which was characterized by glomerulo-
sclerosis, crescent formation, tubular cast deposition,
increased mesangial matrix, and diffuse perivascular andinterstitial mononuclear cell infiltration. All of these
pathological injuries were attenuated in the G-CSF group
(P < 0.05, Fig. 2a). G-CSF treatment also suppressed glom-
erular deposition of IgG (P < 0.05, Fig. 2b) and C3 (P <
0.01, Fig. 2b) in NZB/W F1 mice.
G-CSF treatment suppressed renal infiltration of
proinflammatory immune cells and decreased numbers of
splenic immune cells
Renal infiltration of leukocyte subsets was analyzed in
NZB/W F1 mice. We found that G-CSF treatment de-
creased renal infiltration of CD45+ leukocytes (P < 0.01,
Fig. 3a), CD3+, CD4+ and CD8+ T cells (P < 0.05, Fig. 3b)
when compared to that in the PBS group. Renal infiltra-
tion of myeloid cells (CD11b+) cells was also decreased
in the G-CSF group (P < 0.01, Fig. 3c). However, num-
bers of renal CD19+ B cells (Fig. 3b), CD11c+ dendritic
cells (Fig. 3d), and NK cells (NK1.1+CD3-, Fig. 3e) were
similar between the two groups.
In the spleen, G-CSF treatment decreased the numbers
of splenocytes (P < 0.01, Fig. 4a) including CD19+ B cells,
CD3+ T cells, CD4+ T cells, and CD8+ T cells (Fig. 4b).
Although there was no difference in the number of
splenic CD11b+ myeloid cells (Fig. 4c), G-CSF treatment
decreased numbers of splenic dendritic cells (P < 0.01,
Fig. 4d) and NK cells (P < 0.05, Fig. 4e), when compared
to the PBS group. In addition, the numbers of follicular
helper T cells (CD4+CXCR5+PD-1+, P < 0.05, Fig. 4f ) and
plasma cells (CD138hiCD19low, P < 0.01, Fig. 4g) were
also lower in the G-CSF group than in the PBS group.
G-CSF treatment induced expansion of CD4+CD25+Foxp3+
Tregs
The proportion and absolute numbers of CD4+CD25
+Foxp3+ Tregs were evaluated in both the kidneys and
spleen of NZB/W F1 mice (Fig. 5a-c). G-CSF treatment
induced significant expansion of renal CD4+CD25
+Foxp3+ Tregs in both proportion (P < 0.01, Fig. 5b) and
absolute numbers (P < 0.05, Fig. 5b). Among CD4+Foxp3
+ T cells in the kidney, the number of CD4+CD25-Foxp3
+ cells was decreased by G-CSF treatment (P < 0.05,
Fig. 5b). G-CSF treatment also increased the proportion
of CD4+CD25+Foxp3+ Tregs in the spleen (P < 0.05,
Fig. 2 (See legend on next page.)
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Fig. 2 G-CSF treatment ameliorated histologic injury and immune deposits in lupus nephritis. a Representative kidney sections stained with PAS
(200×; histological score on the right-panel). b Frozen sections stained for IgG and C3 deposits (200×; immunofluorescence staining score on the
right-panel). Scores of both histologic injury and immune deposits were lower in the G-CSF group than the PBS group. Differences in histologic
injury and immune deposit scores were analyzed by t tests. The data are expressed as the mean ± standard error of the mean, with n = 14 − 16
mice per group. White and black bars indicate the G-CSF group and the PBS group, respectively. *P < 0.05, **P < 0.01 for comparisons between
the G-CSF and the PBS groups. C3: complement component 3; G-CSF, granulocyte colony-stimulating factor: PAS, periodic acid-Schiff’s reagent;
PBS: phosphate-buffered saline
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mechanism of G-CSF-mediated renal protection in
NZB/W F1 mice, we decreased Tregs by PC61 treatment
during G-CSF treatment (Additional file 1) and found
that Treg reduction abrogated beneficial effects of G-
CSF on proteinuria (Fig. 1a).
G-CSF treatment decreased numbers of CD11b+Ly6G
+Ly6Clow and CD11b+Ly6G-Ly6Chigh myleoid cells
Among CD45+CD11b+ myeloid cells, Ly6G-Ly6Chigh cells
are considered to be inflammatory monocytes or mono-
cytic MDSCs, and Ly6G+Ly6Clow cells are inflammatory
granulocytes or granulocytic MDSCs. In spleen, G-CSF
treatment decreased proportions and absolute numbers of
both Ly6G+Ly6Clow and Ly6G-Ly6Chigh cells (Fig. 6a). Fur-
thermore, G-CSF treatment decreased renal infiltration of
Ly6G+Ly6Clow and Ly6G-Ly6Chigh cells; however, impact
on Ly6G+Ly6Clow was not statistically significant (Fig. 6b).Fig. 3 G-CSF treatment attenuated renal infiltration of inflammatory leukoc
significantly decreased in the G-CSF group (P < 0.01). b Number of infiltratin
in the G-CSF group (P < 0.05), whereas number of infiltrating B cells (CD19+
in the G-CSF group than in the PBS group (P < 0.01). d-e However, G-CSF d
NK cells (NK1.1+CD3-, e). Flowcytometric analysis was used for quantifying
the mean, with n = 4 − 5 mice per group. White and black bars indicate the
comparisons between the G-CSF and the PBS groups using t-test. G-CSF: gG-CSF treatment suppressed expression of
proinflammatory cytokines in NZB/W F1 mice
G-CSF treatment decreased levels of MCP-1, IL-6, and
TNF-α in either serum (Fig. 7a) or renal tissues (Fig. 7b).
G-CSF treatment also decreased expression of IL-2, IL-
10, and IL-17, which are important type 1 helper T cells
(Th1), type 2 helper T cells (Th2), and type 17 helper T
cells (Th17) cytokines, respectively. Overall, G-CSF
treatment decreased expression of proinflammatory che-
mokine and cytokines in renal tissues as well as system-
ically in NZB/W F1 mice.
Low-dose G-CSF treatment did not expand regulatory T
cells or ameliorate lupus nephritis
When we administered 250 μg/kg of G-CSF 3 times a
week, G-CSF did not attenuate proteinuria (Additional file
2a) or mortality (Additional file 2b). There was no signifi-
cant difference in either anti-ds DNA levels (Additionalytes. a Absolute number of total leukocytes (CD45+) in kidney was
g T cells (CD3+) including both CD4+ and CD8+ T cells was decreased
) was not decreased. c Numbers of CD11b+ myeloid cells were lower
id not decrease renal infiltration of either CD11c+ dendritic cells (d) or
renal cell types. The data are expressed as the mean ± standard error of
G-CSF group and the PBS group, respectively. *P < 0.05, **P < 0.01 for
ranulocyte colony-stimulating factor; PBS: phosphate-buffered saline
Fig. 4 G-CSF treatment decreased numbers of splenic immune cells. a Absolute number of total splenocytes was lower in the G-CSF
group (P < 0.01). b Numbers of B cell (CD19+), T cells (CD3+), and T cell subsets (CD4+, CD8
+) were decreased by G-CSF treatment. c-e Number of
CD11b+ myeloid cells (c) was not significantly decreased by G-CSF, whereas numbers of CD11c+ dendritic cells (d) and NK cells (NK1.1+CD3-, e) were
significantly lower in the G-CSF group. f-g Numbers of both follicular helper T cells (CD4+CXCR5+PD-1+, f) and plasma cells (CD19lowCD138hi, g) were
lower in the G-CSF group. Flowcytometric analysis was used for quantifying spleen cell types. The data are expressed as the mean ± standard
error of the mean, with n = 4 − 5 mice per group. White and black bars indicate the G-CSF group and the PBS group, respectively. *P < 0.05,
**P < 0.01 for comparisons between the G-CSF and the PBS groups using t-test. G-CSF: granulocyte colony-stimulating factor; PBS: phosphate-
buffered saline
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logic injury was also not improved (Additional file 2e).
In parallel, Tregs were not expanded in kidneys
(Additional file 2f ) or spleen (Additional file 2g).
Low-dose GCF treatment did not decrease inflamma-
tory granulocytes (Additional file 2h-i).”
Discussion
This study demonstrated that G-CSF treatment decreased
proteinuria, serum levels of BUN and creatinine, and ul-
timately decreased mortality of NZB/W F1 mice through
the expansion of Tregs. G-CSF treatment also decreased
serum levels of anti-dsDNA, increased serum levels of
C3, and attenuated renal tissue injury including depos-
ition of IgG and C3 in NZB/W F1 mice. Furthermore, G-
CSF treatment induced expansion of CD4+CD25+Foxp3+
Tregs, with decreased renal infiltration of T cells, B cells,inflammatory granulocytes and monocytes rather than
MDSCs. G-CSF treatment also decreased expression of
MCP-1, IL-6, TNF-α, IL-2, IL-10, and IL-17.
Chronic treatment of low-dose G-CSF (10 μg/kg) ag-
gravated lupus nephritis in MRL/lpr mice, where these
results might be attributed to increased Th2 cytokines
and IFN-α [3, 7, 13]. Conversely, chronic treatment of
high-dose G-CSF (200 μg/kg) attenuated lupus nephritis
in MRL/lpr mice by potentially decreasing glomerular
expression of FcRγIII and IL-12 production [13]. The G-
CSF dose in this study was comparable to the high-dose
of G-CSF in the previous study [13]. When we reduced G-
CSF dose by 40 %, we could not ameliorate lupus neph-
ritis. Proinflammatory chemokines (MCP-1) and cytokines
(IL-6, TNF-α), Th1 cytokines (IL-2, IFN-γ), Th2 cytokines
(IL-4, IL-10), and Th17 cytokines (IL-17A) are involved in
pathogenesis of lupus nephritis, and are therapeutic
Fig. 5 G-CSF treatment induced expansion of CD4+CD25+Foxp3+ regulatory T cells in both spleen and kidney. a Representative flow cytometric
dot plots of CD25+Foxp3+ cells in kidney (CD45+CD4+ gated) and spleen (CD4+ gated). b-c Bar graphs showed proportions of Foxp3+, CD25
+Foxp3+, and CD25-Foxp3+ among CD4+ T cells or absolute numbers of CD4+Foxp3+, CD4+CD25+Foxp3+, and CD4+CD25-Foxp3+ in kidneys (b)
and spleen (c). The data are expressed as the mean ± standard error of the mean, with n = 4 − 5 mice per group. White and black bars indicate
the G-CSF group and the PBS group, respectively. *P < 0.05, **P < 0.01 for comparisons between the G-CSF and the PBS groups using t-test.
G-CSF: granulocyte colony-stimulating factor; PBS: phosphate-buffered saline; Tregs: regulatory T cells
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Fig. 6 (See legend on next page.)
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Fig. 6 G-CSF treatment decreased numbers of CD11b+Ly6G+Ly6Clow and CD11b+Ly6G-Ly6Chigh myeloid cells. a Flow cytometric dot plots for
Ly6G and Ly6C defined CD11b+Ly6G+Ly6Clow and CD11b+Ly6G-Ly6Chigh cells in spleen (CD11b+ gated). Bar graphs on the left side showed
proportions of CD11b+Ly6G+Ly6Clow and CD11b+Ly6G-Ly6Chigh cells among total splenocytes. Bar graphs on the right side indicated absolute
numbers of CD11b+Ly6G+Ly6Clow and CD11b+Ly6G-Ly6Chigh cells in spleen. b Flow cytometric dot plots for Ly6G and Ly6C defined CD11b+Ly6G
+Ly6Clow and CD11b+Ly6G-Ly6Chigh cells in kidney (CD45+CD11b+ gated). Bar graphs on the left side showed proportions of CD11b+Ly6G
+Ly6Clow and CD11b+Ly6G-Ly6Chigh cells among renal CD45+ cells. Bar graphs on the right side indicated absolute numbers of CD11b+Ly6G
+Ly6Clow and CD11b+Ly6G-Ly6Chigh cells in kidney. The data are expressed as the mean ± standard error of the mean, with n = 4 − 5 mice per
group. White and black bars indicate the G-CSF group and the PBS group, respectively. *P < 0.05, **P < 0.01 for comparisons between the G-CSF
and the PBS groups using t-test. G-CSF: granulocyte colony-stimulating factor; PBS: phosphate-buffered saline; Tregs: regulatory T cells
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creased the levels of these pathogenic chemokine/cyto-
kines such as MCP-1, IL-6, TNF-α, IL-2, IL-10, and IL-17,
and thus were consistent with its suppressive effects on
both innate and adaptive immune cells in NZB/W F1Fig. 7 G-CSF treatment decreased levels of proinflammatory chemokine an
proinflammatory chemokine (MCP-1), proinflammatory cytokines (IL-6, TNF-
kines (IL-17A) were measured in serum (a) and renal tissues (b). G-CSF trea
and IL-17. In renal tissues, G-CSF treatment significantly decreased levels of
standard error of the mean, with n = 4 − 7 mice per group. White and blac
0.05, **P < 0.01 for comparisons between the G-CSF and the PBS groups us
IL: interleukin; MCP-1: monocyte chemoattractant protein-1; PBS: phosphate
regulatory T cellsmice. Despite reduced IL-10 levels, reduced levels of IL-6
in both serum and renal tissues might have contributed
towards Treg expansion by G-CSF treatment. Taken to-
gether, these results indicated that the suppression of vari-
ous proinflammatory cytokines involved in lupus nephritisd cytokines in the serum and kidneys. Expression levels of
α), Th1 cytokines (IL-2, INF-γ), Th2 cytokines (IL-4, IL-10), and Th17 cyto-
tment significantly decreased serum levels of MCP-1, IL-6, TNF-α, IL-10
MCP-1, IL-6, IL-2, and IL-10. The data are expressed as the mean ±
k bars indicate the G-CSF group and the PBS group, respectively. *P <
ing t-test. G-CSF: granulocyte colony-stimulating factor; IFN: interferon;
-buffered saline; Th: helper T cells; TNF: tumor necrosis factor; Tregs:
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tenuation of lupus nephritis.
G-CSF decreased inflammatory granulocytes (CD11b
+Ly6G+Ly6Clow) or monocytes (CD11b+Ly6G-Ly6Chigh) in
both kidney and spleen. These results were consistent
with previous studies in murine lupus models. In those
studies, the percentage of CD11b+Gr-1low monocytes in
the kidney increased as the disease progressed in the
MRL/lpr mouse model of lupus, and it expanded in B6
mice with established chronic graft-versus-host disease
[12, 25]. Although inflammatory granulocytes and mono-
cytes share surface markers with the MDSCs, these data
suggested that G-CSF treatment decreased inflammatory
granulocytes and monocytes rather than MDSCs in paral-
lel with improvement of lupus nephritis.
We found that Tregs expanded in the G-CSF group and
Treg depletion abrogated the G-CSF-mediated beneficial
effects on proteinuria in NZB/W F1 mice. These findings
were consistent with a previous study, which demonstrated
that G-CSF recruited Tregs, and thereby prevented onset of
spontaneous diabetes in NOD mice [26]. CD4+CD25+ Treg
cells were decreased in SLE patients and Treg cell numbers
were inversely correlated with disease activity [27, 28].
Moreover, infusion of Tregs attenuated disease progression
and reduced mortality in murine lupus [29]. Therefore, we
assumed that Treg expansion could be the beneficial mech-
anism of G-CSF on lupus nephritis in this study. Although
MDSC could contribute to induction of Tregs [30], lack of
MSDC expansion might exclude this mechanism in our
setting. It was also observed that G-CSF decreased CD25-
Foxp3+ T cells in contrast to CD25+Foxp3+ Tregs. These
results demonstrated another benefit of G-CSF treatment
for lupus nephritis, because CD25-Foxp3+ T cells were in-
creased in the case of active lupus nephritis and had lower
suppressive activity than CD25+Foxp3+ Tregs [31, 32].
Beneficial effects of G-CSF for lupus nephritis ob-
served in this study suggest G-CSF as potential treat-
ment for lupus nephritis, considering G-CSF is already
used in clinical treatment of neutropenia after chemo-
therapy. Human G-CSF is less potent in mice than mur-
ine G-CSF, thus we used a very high dose of human G-
CSF in NZB/W F1 mice. We expect to reduce this dose
to tolerable levels in clinical trials.
Most patients with lupus nephritis take long-term im-
munosuppressants such as corticosteroids, cyclophospha-
mide, or mycophenolate mofetil. Therefore, one of the
limitations of this study is that we did not evaluate the
interacting effects of G-CSF with standard immuosup-
pressants for lupus nephritis. Further studies are needed
to confirm our findings in clinically plausible situations.
Conclusions
G-CSF treatment ameliorated lupus nephritis, and prefer-
ential expansion of CD4+CD25+Foxp3+ Tregs instead ofMDSC may be the underlying mechanism. Therefore, G-
CSF may have a therapeutic potential for lupus nephritis.
Additional files
Additional file 1: PC61 treatment markedly decreased regulatory T cells
in both kidneys and spleen. During G-CSF treatment, we administered
anti-CD25 depleting antibodies (PC61) at a dose of 0.5 mg 3 times a
week from 33 weeks to 36 weeks. At harvest, regulatory T cells were
depleted in spleen and markedly decreased in kidneys in the G-CSF
plus PC61 group. (TIF 4173 kb)
Additional file 2: Low-dose G-CSF treatment did not expand regulatory
T cells or ameliorate lupus nephritis. When we administered 250 μg/kg
of G-CSF 3 times a week, G-CSF did not attenuate proteinuria (a) or
mortality (b). There was no significant difference in either anti-ds DNA
levels (c) or serum C3 levels (d). Histologic injury was also not improved
(e). In parallel, Tregs were not expanded in kidneys (f) or spleen (g).
Low-dose GCF treatment did not decrease inflammatory granulocytes
or monocytes in kidney (h) or spleen (i). (TIF 2014 kb)
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